Five Prime Therapeutics is a biotechnology company that aims to develop protein therapeutics for treating cancer and inflammatory diseases. Its leading product candidate, FPA008, is an antibody that blocks colony stimulating factor-1 receptor and is currently in Phase Ib clinical trials for rheumatoid arthritis. The company also has plans to develop FPA008 for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Overall, Five Prime Therapeutics is focused on advancing its clinical pipeline and improving patient outcomes.